{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T08:42:25Z","timestamp":1773909745354,"version":"3.50.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T00:00:00Z","timestamp":1679875200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","award":["175:1298\u2013304"],"award-info":[{"award-number":["175:1298\u2013304"]}],"id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011957","name":"Millennium Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011957","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.clml.2023.03.007","type":"journal-article","created":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T04:50:53Z","timestamp":1680065453000},"page":"491-504","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Ixazomib Versus Placebo as Postinduction Maintenance Therapy in Newly Diagnosed Multiple Myeloma Patients: An Analysis by Age and Frailty Status of the TOURMALINE-MM4 Study"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4539-6363","authenticated-orcid":false,"given":"Sara","family":"Bringhen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lud\u011bk","family":"Pour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reuben","family":"Benjamin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Grosicki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-Ki","family":"Min","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle Leao","family":"C\uff0e de Farias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Vorog","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard J.","family":"Labotka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bingxia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dasha","family":"Cherepanov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren E.","family":"Cain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sudhakar","family":"Manne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5862-1833","authenticated-orcid":false,"given":"S. Vincent","family":"Rajkumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8990-3254","authenticated-orcid":false,"given":"Meletios A.","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2023.03.007_bib0001","series-title":"SEER Cancer Statistics Review, 1975-2013","year":"2015"},{"key":"10.1016\/j.clml.2023.03.007_bib0002","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1182\/blood-2011-06-358812","article-title":"Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)","volume":"118","author":"Palumbo","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.03.007_bib0003","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41408-020-00359-2","article-title":"Multiple myeloma current treatment algorithms","volume":"10","author":"Rajkumar","year":"2020","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2023.03.007_bib0004","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/CCO.0000000000000395","article-title":"Elderly patients with multiple myeloma: towards a frailty approach?","volume":"29","author":"Zweegman","year":"2017","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.clml.2023.03.007_bib0005","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1038\/s41375-020-0918-6","article-title":"Defining the vulnerable patient with myeloma-a frailty position paper of the European Myeloma Network","volume":"34","author":"Cook","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2023.03.007_bib0006","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/bjh.14193","article-title":"Multiple myeloma: practice patterns across Europe","volume":"175","author":"Raab","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2023.03.007_bib0007","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(18)30687-9","article-title":"Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial","volume":"20","author":"Jackson","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2023.03.007_bib0008","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","article-title":"Continuous lenalidomide treatment for newly diagnosed multiple myeloma","volume":"366","author":"Palumbo","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2023.03.007_bib0009","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1038\/s41375-018-0142-9","article-title":"Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN)","volume":"32","author":"Larocca","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2023.03.007_bib0010","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.03.007_bib0011","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(18)33003-4","article-title":"Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"393","author":"Dimopoulos","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2023.03.007_bib0012","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1007\/s00277-020-04149-5","article-title":"Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma","volume":"99","author":"Kaiser","year":"2020","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2023.03.007_bib0013","doi-asserted-by":"crossref","first-page":"4030","DOI":"10.1200\/JCO.20.02060","article-title":"Ixazomib as postinduction maintenance for patients with newly diagnosed multiple myeloma not undergoing autologous stem cell transplantation: the phase III TOURMALINE-MM4 trial","volume":"38","author":"Dimopoulos","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.03.007_bib0014","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2023.03.007_bib0015","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.3324\/haematol.2019.226407","article-title":"Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial","volume":"105","author":"Bringhen","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2023.03.007_bib0016","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1038\/leu.2016.36","article-title":"A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma","volume":"30","author":"Larocca","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2023.03.007_bib0017","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1007\/s00277-016-2835-3","article-title":"Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA\/GEM05 trials","volume":"95","author":"Mateos","year":"2016","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2023.03.007_bib0018","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","article-title":"Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial","volume":"395","author":"Mateos","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2023.03.007_bib0019","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1200\/JCO.2016.66.7295","article-title":"Updated outcomes and impact of age with lenalidomide and low-dose dexamethasone or melphalan, prednisone, and thalidomide in the randomized, phase III FIRST trial","volume":"34","author":"Hulin","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.03.007_bib0020","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2023.03.007_bib0021","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/j.1600-0609.2011.01665.x","article-title":"Responsiveness and minimal important score differences in quality-of-life questionnaires: a comparison of the EORTC QLQ-C30 cancer-specific questionnaire to the generic utility questionnaires EQ-5D and 15D in patients with multiple myeloma","volume":"87","author":"Kvam","year":"2011","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2023.03.007_bib0022","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/ejh.13379","article-title":"Quality of life is maintained with ixazomib maintenance in post-transplant newly diagnosed multiple myeloma: the TOURMALINE-MM3 trial","volume":"104","author":"Schjesvold","year":"2020","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2023.03.007_bib0023","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/ejh.13316","article-title":"Estimation of minimally important differences and responder definitions for EORTC QLQ-MY20 scores in multiple myeloma patients","volume":"103","author":"Sully","year":"2019","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2023.03.007_bib0024","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/978-3-319-40320-5_8","article-title":"Treatment of newly diagnosed elderly multiple myeloma","volume":"169","author":"Fouquet","year":"2016","journal-title":"Cancer Treat Res"},{"key":"10.1016\/j.clml.2023.03.007_bib0025","doi-asserted-by":"crossref","first-page":"910","DOI":"10.3324\/haematol.2016.162693","article-title":"A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients","volume":"102","author":"Engelhardt","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2023.03.007_bib0026","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.3324\/haematol.2019.242958","article-title":"Structured assessment of frailty in multiple myeloma as a paradigm of individualized treatment algorithms in cancer patients at advanced age","volume":"105","author":"Engelhardt","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2023.03.007_bib0027","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1182\/asheducation-2018.1.83","article-title":"Treatment approach for the older, unfit patient with myeloma from diagnosis to relapse: perspectives of a European hematologist","volume":"2018","author":"Facon","year":"2018","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.03.007_bib0028","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1016\/S2152-2650(20)30470-5","article-title":"Management of frail older adults with newly diagnosed multiple myeloma: moving toward a personalized approach","volume":"20","author":"Grant","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2023.03.007_bib0029","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1182\/asheducation-2018.1.88","article-title":"Approach to the treatment of the older, unfit patient with myeloma from diagnosis to relapse: perspectives of a US hematologist and a geriatric hematologist","volume":"2018","author":"Wildes","year":"2018","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2023.03.007_bib0030","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.3324\/haematol.2016.148189","article-title":"Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores","volume":"101","author":"Engelhardt","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2023.03.007_bib0031","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1001\/jamaoncol.2016.0931","article-title":"An appraisal of clinically meaningful outcomes guidelines for oncology clinical trials","volume":"2","author":"Kumar","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clml.2023.03.007_bib0032","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/bjh.16945","article-title":"Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, Phase III trial","volume":"192","author":"Jackson","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2023.03.007_bib0033","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/s41375-019-0595-5","article-title":"The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial","volume":"34","author":"Pawlyn","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2023.03.007_bib0034","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2023.03.007_bib0035","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1038\/s41375-021-01488-8","article-title":"Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA","volume":"36","author":"Facon","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2023.03.007_bib0036","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1038\/s41375-020-0876-z","article-title":"Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)","volume":"34","author":"Terpos","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2023.03.007_bib0037","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/blood-2017-07-795047","article-title":"Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma","volume":"131","author":"Facon","year":"2018","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023000939?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023000939?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:41:50Z","timestamp":1761871310000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265023000939"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S2152265023000939"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2023.03.007","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ixazomib Versus Placebo as Postinduction Maintenance Therapy in Newly Diagnosed Multiple Myeloma Patients: An Analysis by Age and Frailty Status of the TOURMALINE-MM4 Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2023.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}